UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the Quarterly Period Ended March 31, 2020 or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from ___________ to ___________ Commission File Number: 1-14106 DAVITA INC. 2000 16th Street Denver, CO 80202 Telephone number (720) 631-2100 Securities registered pursuant t ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the Fiscal Year Ended December 31, 2019 or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from ___________ to ___________ Commission File Number: 1-14106 DAVITA INC. (Exact name of registrant as specified in charter) Delaware 51-0354549 (State of incorporation) (I.R.S. ...

DaVita Inc. (NYSE:DVA) Q4 2019 Earnings Conference Call February 10, 2020 5:00 PM ET Company Participants Jim Gustafson - Vice President, Investor Relations Javier Rodriguez - Chief Executive Officer Joel Ackerman - Chief Financial Officer LeAnne Zumwalt - Group Vice President Jim Hilger - Chief Accounting Officer Conference Call Participants Justin Lake - Wolfe Research Kevin Fischbeck - Bank of America Pito Chickering - Deutsche Bank Stephen Tanal - Goldman Sachs Whit Mayo - UBS Gary Taylor - JPMorgan Jus ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the Quarterly Period Ended September 30, 2019 or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from ___________ to ___________ | --- | --- | --- | |----------------------------------------------------------------|-------------------|--------------------| | Commissi ...

DaVita Inc. (NYSE:DVA) Q3 2019 Earnings Conference Call November 5, 2019 5:00 PM ET Company Participants Jim Gustafson - Vice President, Investor Relations Javier Rodriguez - Chief Executive Officer Joel Ackerman - Chief Financial Officer LeAnne Zumwalt - Group Vice President Jim Hilger - Chief Accounting Officer Conference Call Participants Stephen Tanal - Goldman Sachs Kevin Fischbeck - Bank of America Justin Lake - Wolfe Research Pito Chickering - Deutsche Bank Whit Mayo - UBS Gary Taylor - JPMorgan John ...

DaVita Inc. (NYSE:DVA) Q2 2019 Earnings Conference Call August 1, 2019 5:00 PM ET Company Participants Jim Gustafson - VP, IR Javier Rodriguez - CEO Joel Ackerman - CFO LeAnne Zumwalt - Group VP Conference Call Participants Kevin Fischbeck - Bank of America Justin Lake - Wolfe Research Pito Chickering - Deutsche Bank Steve Tanal - Goldman Sachs Whit Mayo - UBS Gary Taylor - JPMorgan Matthew Gillmor - Baird Matt Larew - William Blair Operator Good evening. My name is Darin, and I will be your conference faci ...

DaVita Inc. (NYSE:DVA) Q1 2019 Earnings Conference Call May 7, 2019 5:00 PM ET Company Participants Jim Gustafson - Vice President, Investor Relations Kent Thiry - Chairman and Chief Executive Officer Joel Ackerman - Chief Financial Officer Javier Rodriguez - Chief Executive Officer, DaVita Kidney Care Conference Call Participants Kevin Fischbeck - Bank of America Justin Lake - Wolfe Research Steve Tanal - Goldman Sachs Whit Mayo - UBS Gary Taylor - J. P. Morgan John Ransom - Raymond James Operator Good eve ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the Quarterly Period Ended March 31, 2019 Commission File Number: 1-14106 | --- | --- | |---------------------------------------|-------| | | | | 2000 16th Street | | | Denver, CO 80202 | | | Telephone number (720) 631-2100 | | Delaware 51-0354549 (State of incorporation) Employer Identification No.) Indicate by check mark whether the r ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Emerging growth company ☐ FORM 10-K ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the Fiscal Year Ended December 31, 2018 Commission File Number: 1-14106 DAVITA INC. (Exact name of registrant as specified in charter) Delaware 51-0354549 (State of incorporation) (I.R.S. Employer Identification No.) 2000 16th Street Denver, CO 80202 Telephone number (720) 631-2100 Securities registered pursuant t ...

Financial Data and Key Metrics Changes - The adjusted operating income for Q4 2018 was $370 million, with a full-year total of $1.513 billion, aligning with guidance [13] - Operating cash flow from continuing operations was $307 million for Q4 and $1.48 billion for the year, consistent with previous guidance [27] - The effective tax rate for Q4 was 24.3%, while the annual rate was 29.2%, with Q4's rate being unusually low due to positive quarterly true-ups [25][26] Business Line Data and Key Metrics Changes - In the U.S. Dialysis and Lab Segment, treatment per day growth in Q4 was 3.1%, with normalized non-acquired growth at 2.6% [21] - Revenue per treatment decreased by $0.65 from Q3 to Q4, but excluding calcimimetics, it increased by over $1 sequentially [22] - DaVita Rx revenue declined by approximately $100 million quarter-over-quarter due to the wind down of the business [23] Market Data and Key Metrics Changes - The commercial mix was down approximately 10 basis points from 10.5% in 2017 to 10.4% in 2018, reflecting demographic headwinds [22] - The company expects U.S. total treatment volume growth of 3% to 4% and revenue per treatment growth of 0% to 1% for 2019 [28] Company Strategy and Development Direction - The company is focusing on integrated care capabilities to improve patient outcomes and reduce costs [19] - There is an emphasis on home dialysis, with over 13,000 new home patients trained in 2018, as it is more capital efficient [15] - The company is working on obtaining FTC approval for the DMG transaction, which is expected to improve financial performance significantly in 2019 [10][11] Management's Comments on Operating Environment and Future Outlook - Management noted a slowdown in growth due to various factors, including increased transplantation availability and comorbid conditions affecting ESRD patient numbers [35][36] - The company is optimistic about future Medicare fee-for-service rate increases, which are expected to be better than previous years [32] - Management is cautious about the impact of California legislation on financial performance, estimating a potential revenue impact of $25 million to $40 million if the legislation passes [44][66] Other Important Information - The company plans to reduce capital expenditures in 2019, with expected CapEx between $800 million and $840 million, down from $902 million in 2018 [28][30] - The international business is expected to achieve positive operating income in 2019, excluding foreign exchange impacts [25] Q&A Session Summary Question: Update on DMG transaction - Management remains confident about the DMG transaction closing, but timing is uncertain due to the government shutdown [34][41] Question: Factors affecting treatment growth slowdown - Management identified upstream comorbid conditions and increased organ availability as contributing factors to the slowdown [35][36] Question: Financial impact of California legislation - Management estimates a potential revenue impact of $25 million to $40 million if the legislation passes [44][66] Question: Home dialysis growth - Home dialysis growth is included in the treatment growth figures, and the company is committed to expanding this area [45] Question: CapEx for new centers - Management indicated a significant slowdown in new center openings for 2019 due to changing patient needs and growth in home dialysis [48] Question: Commercial contracting expectations - Management expects the commercial book to be down 1% to up 0.5% in 2019 [72] Question: Medicare Advantage penetration - Management did not disclose current Medicare Advantage mix but indicated it could align with overall market trends [78][110]